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INTRODUCTION
Crocus sativus L. is a small perennial stemless herb 
from the iris family (Iridaceae), commonly known 
as saffron, that is widely cultivated in many regions 
of the globe1. Phytochemical components of saffron 
have been extensively reported, in which safranal, 
picrocrocin and crocetin glycosides, like crocin, are 
major components and responsible for the typical red 
color, bitter taste and aroma respectively2. C. sativus 
possesses a wide array of medicinally important ac-
tivities, such as anticonvulsant, antihypertensive, an-
titussive and antigenotoxic effects3. Crocin is one of 
the major constituents of the stigma of the plant and 
is the diester formed from the disaccharide gentiobi-
ose and the dicarboxylic acid crocetin (Figure 1). It is 
characterized as an unsually soluble carotenoid, while 
it presents striking coloring and flavoring capabilities. 
It has also been shown to have antidepressant, anx-
iolytic, antioxidant4,5, antithrombotic6,7, antiinflamma-
tory and mainly anticancer activities8,9. Among others, 
it improves memory and learning skills and presents 
neuroprotective properties10. 
In the present work, we conducted a comparative 
study of the in vitro effect of crocin on cultured human 
lymphocytes from peripheral blood of three leukemic 
patients and of one healthy individual, by estimating 
the frequency of sister chromatid exchanges (SCEs) 
and the values of proliferation rate index (PRI).
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The study of SCE frequency is a very sensitive, 
reliable and rapid method for detecting genotoxic-
ity, which has lately been proposed also as one of the 
methods for evaluating chemotherapeutic efficiency 
in vitro and in vivo. Elevated SCE values are attrib-
uted to chromosomal instability, due to genetic or 
environmental factors (radiation, chemical and bio-
logical mutagens). Furthermore, PRI has been estab-
lished as a sensitive indicator for the evaluation of the 
cytostatic activity of various enviromental hazards or 
therapeutic agents11, since it reflects the effect of the 
different mutagenic agents in the cell cycle. The aim 
of our study was to test the hypothesis that the SCE 
assay in vitro can be used for the prediction of the in 
vivo tumor response to the potential chemotherapeu-
tic action of crocin. 
MATERIALS AND METHODS
In vitro SCE and PRI assays
To conduct the study, blood was taken from three 
women with chronic lymphocytic leukemia, 62-69 
years old, that haven’t undergone any treatment prior 
to blood collection and from one healthy donor, same 
gender and age. All blood donors were nonsmokers 
and no alcohol consumers. Human lymphocyte cul-
tures were prepared by adding in 5mL of the chromo-
some medium (RPMI-1640; Biochrome, supplement-
ed with 20% fetal calf serum, 0,63% L-glutamine, 
0,63% penicillin/streptomycin and 2% phytohaemag-
glutinin) 11–12 drops of heparinized whole blood, 5 
μg/mL 5-bromodeoxyuridine (BrdU) solution and 
aqueous solutions (100ng, 1μg and 10μg final concen-
tration per culture) of crocin (Sigma) at the beginning 
of culture life. The cultures were incubated at 37oC 
for 72 hours in the dark to minimize photolysis of 
5-bromodeoxyuridine. Colchicine (0,3 μg/mL) was 
added 2 hours before the collection of the cultures. 
The cells were then collected by centrifugation and 
exposed to 0,075M KCl for 10 min. The hypotonic 
solution spreads the chromosomes and hemolyses the 
red blood cells. The pellet was fixed three times with 
methanol: acetic acid (3:1). Drops of concentrated 
suspension of cells were placed on microslides and 
then allowed to air-dry. For SCE and PRI analysis, 
the slides were stained by a modification of the fluo-
rescence plus Giemsa procedure to obtain harlequin 
chromosomes12. 
RESULTS
We have studied the cytogenetic behaviour of crocin 
by estimating the SCE frequency (Table 1) and PRI 
values (Table 2) in human lymphocyte cultures from 
three leukemic patients and one healthy individual. 
We have investigated the effect of three different cro-
cin concentrations (100ng, 1μg and 10μg final con-
centrations). The results showed that a statistically 
significant decrease of the SCE frequency of lympho-
cytes from leukemic donors had been observed after 
crocin affection, though the SCEs of healthy donor 
cells presented a slight, non significant, increase (Fig-
ure 2). Contrariwise, all tested crocin solutions did 
not cause remarkable changes to the PRI values of 
the lymphocytes neither of the leukemic, nor of the 
healthy donors, after statistical analysis (Figure 3). 
Both the SCE’s reduction of the lymphocytes from 
leukemic patients and the SCE frequency’s increase 
of the cells from healthy donor were proportional to 
the concentrations of crocin solutions.
As far as the cultured lymphocytes of leukemic pa-
tients are concerned, we have observed in all of them 
a great increase in the frequency of SCEs compared 
to the control value of the healthy donor. Furthero-
more, all tested concentrations of crocin have caused 
a statistically significant decrease (p < 0,001) of SCE 
frequency to the first leucemic patient lymphocytes, 
whereas only the higher crocin concentrations of 1μg 
and 10μg have brought a statistically significant de-
Figure. 1. Chemical structure of crocin.
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crease (p < 0,001) on the cultured lymphocytes of the 
other two patients. On the other hand, the PRI values 
of lymphocytes of all leukemic donors were slightly 
decreased compared to the healthy individual after the 
crocin effect, but they were not significantly affected 
at any crocin concentration tested. 
Statistical analysis
For SCE estimation, at least 30 properly spread meta-
phases of cells in second division from each culture 
were blindly scored. For PRI calculation, 100 meta-
phases in the first, second, third and higher divisions 
from each culture were blindly scored. The PRI was 
calculated according to the formula: PRI = (M1 +2M2 
+3M3+…. )/N, where “M1, M2, M3+… ” indicate the 
number of metaphases corresponding to first, second, 
third or subsequent divisions, respectively, and “N” is 
the total number of metaphases scored (at least 100) 
for each culture. For the statistical evaluation of the 
experimental data, Student’s t-test was performed to 
determine whether any SCE values differed signifi-
cantly from the controls and the x2-test was used for 
PRI comparisons.
DISCUSSION
Crocin, the main pigment of Crocus sativus L has been 
shown to exhibit antitumor activity against many hu-
man tumors. Although sufficient number of scientists 
investigates the antineoplastic effect of crocin lately, 
the involved mechanisms are only poor understood. 
Sun Y et al suggested that crocin induced apoptosis and 
cell cycle arrest and regulated Bcl-2 and Bax expres-
sion of HL-60 cells. In their experiments the results 
showed that crocin (0,625-5 mg/mL) inhibited human 
leukemia HL-60 cells proliferation and induced apop-
tosis and cell cycle arrest at G0/G1 phase, in a concen-
tration and time-dependent manner13. These results 
are in agreement with the investigation of Hoshyar R. 
et al who have found that crocin triggered the apopto-
sis through increasing the Bax/Bcl-2 ratio and caspase 
activation in human gastric adenocarcinoma, AGS, 
cells14. Noureini SK and Wink M. proposed that the 
antiproliferative action of crocin is due on telomerase 
inhibition and hTERT (catalytic subunit of telomerase 
gene) down regulation. They have found that telomer-
ase activity of hepatocarcinoma HepG2 cells treated 












(control) 7,82 12,18 9,81 10,42
100 ng 7,94 7,72 a 9,45 9,02
1 μg 7,95 6,36 a 7,5 a 8,4 a
10 μg 7,98 7,68 a 7,9 a 8,52 a
A minimum of 30 metaphases were scored for SCEs from each culture.
a Statistically significant (p < 0,001) decrease over the corresponding control (t-test). 
SCEs, sister chromatid exchanges; SE, standard error.











(control) 2,18 1,97 1,99 1,95
100 ng 2,2 2,02 1,91 1,97
1 μg 2,21 1,89 1,91 1,84
10 μg 2,24 1,95 1,88 1,98
PRI= (M1+M2+M3*)/100, where M1 is the percentage value of cells in the first division, M2 the percentage values of 
cells in the second division and M3* the percentage values of cells in the third and higher division. At least 100 meta-
phases are needed for the PRI calculation.
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Figure 2. SCEs of cultured lymphocytes from normal (C) and leucemic (C1, C2, C3) blood donors after crocin 
administration (100ng, 1μg and 10μg).
Figure 3. PRI values of cultured lymphocytes from normal (C) and leucemic (C1, C2, C3) blood donors after crocin 
administration (100ng, 1μg and 10μg). 
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with 3 mg/ml crocin has been reduced to about 51% 
and hTERT has showed a 60% decrease as compared 
to untreated control cells15. 
Increase SCE values (higher than 8 per each meta-
phase) of human cultured lymphocytes could be either 
due to a large number οf DNA lesions, which could 
not be repaired before the cells reach S phase, and/
or due to the inability of the repair mechanisms to re-
store damages, as usually happens in tumor cells. This 
is confirmed by the elevated SCE frequencies of cul-
tured lymphocytes of the three patients with chronic 
lymphocytic leukemia showed in Table 1. In order to 
evaluate the effect of crocin on DNA consistency and/
or repair enzymes efficacy of leukemic patients’ cul-
tured lymphocytes, we estimated the SCEs and PRI 
of these lymphocytes after the effect of crocin and 
we compared them with the corresponding values 
of healthy blood donor. The significantly diminished 
SCE values of lymphocytes from leukemic patients 
after crocin administration could be attributed not 
only to the lack of crocin-induced DNA damage, but 
also to the reinforcement of repair mechanisms by this 
compound. We could conclude that the DNA of leuke-
mic patients shows increased instability, but the cro-
cin solutions significantly reduce the instability of the 
DNA structure. At first glance these results seem to 
be contrary with the apoptotic and cytotoxic effect of 
crocin that found by a numerous of scientists. Crocin 
however, as Sun Y et al suggested13, affects in a con-
centration and time-dependent manner. 0,625-5 mg/
mL of crocin inhibited HL-60 cell proliferation and 
induced apoptosis, 6.25, 25 mg/kg of crocin inhibited 
the tumor weight and size13. 
3 mg/ml crocin was reduced to about 51% of 
telomerase activity as compared to untreated control 
cells15. The concentrations of crocin solutions in our 
experiment were much lower, 0,02μg/ml, 0,2μg/ml 
and 2μg/ml. Because of SCEs have been frequently 
used as a highly sensitive indicator of DNA damage 
and/or subsequent repair mechanisms, we chose to 
investigate the cytogenetic action of crocin in small 
concetrations. 
The alteration in cell cycle kinetics as indicated 
by the suppression of PRI in lymphocyte cultures has 
been proved to be a very useful and sensitive marker 
of the cytostatic action of various substances, environ-
mental hazards or therapeutic agents9. The cultured 
lymphocytes of patients with leukemia showed sig-
nificant decrease of PRI values compared to the lym-
phocytes of healthy individuals, as expected (Table 2), 
while the small concentrations of crocin (0,02μg/ml, 
0,2μg/ml and 2μg/ml) didn’t cause antiproliferative 
action on them. After the effect of crocin solutions the 
cultured lymphocytes of patients with leukemia pre-
sented non significant change of PRI values. Crocin 
showed strong antiproliferative action in hepatocarci-
noma HepG2 cells at the concentration of 3mg/ml15 
and it exhibited proliferative inhibition on human leu-
kemia HL-60 cells at 5mg/ml16. 
 The results of this investigation are suggested that 
the crocin solutions at small concentrations signifi-
cantly reduce the increased instability of lymphocyte 
DNA from leukemic patients, while they are not af-
fecting the rate of these cells’ cycle. At least at the 
concentrations tested, crocin could be characterized as 
cytoprotective, after the significant reduction of SCEs 
that caused in the leukemic cells, but not as cytostatic, 
since we observed no significant changes in the rate of 
proliferation of these cells. These very interesting re-
sults of the cytogenetic study of crocin require further 
investigation, by expanding to in vivo experiments, 
since crocin could be proven to have also a potential 
chemotherapeutic action.
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ΠΕΡΙΛΗΨΗ: Η κροκίνη είναι ένα από τα κυριότερα συστατικά των στιγμάτων του φυτού Crocus sativus. Παρουσιάζει 
εντυπωσιακές χρωστικές και αρτυματικές ικανότητες, και χορηγείται ως φάρμακο για τη θεραπεία πολλών νοσημάτων. 
Στην παρούσα εργασία πραγματοποιήθηκε συγκριτική μελέτη της in vitro επίδρασης της κροκίνης στο γενετικό υλικό 
λεμφοκυττάρων καλλιεργημένων από περιφερικό αίμα τριών γυναικών με χρόνια λεμφοκυτταρική λευχαιμία, οι οποίες δεν 
είχαν υποβληθεί σε καμία θεραπεία προ της αιμοληψίας και φυσιολογικής μάρτυρος της ιδίας περίπου ηλικίας, με σκοπό 
να διαπιστωθεί αν ο προσδιορισμός της συχνότητας των χρωματιδιακών ανταλλαγών (Sister Chromatid Exchanges, SCEs) 
in vitro μπορεί να χρησιμοποιηθεί για την πρόβλεψη της in vivo ανταπόκρισης του όγκου στην πιθανή χημειοθεραπευτική 
δράση της κροκίνης. Οι SCEs έχουν προταθεί ως μια πολύ ευαίσθητη μέθοδος τόσο για τον προσδιορισμό της γονοτοξι-
κότητας, όσο και για την αξιολόγηση της αποτελεσματικότητας πολλών χημειοθεραπευτικών φαρμάκων in vitro και in 
vivo. Παράλληλα μετρήθηκε ο δείκτης ρυθμού πολλαπλασιασμού (Proliferation Rate Index, PRI) των λεμφοκυττάρων, ο 
οποίος έχει καθιερωθεί ως ένας πολύτιμος δείκτης κυτταροστατικότητας. Τα αποτελέσματα αποκάλυψαν ότι κανένα από τα 
διαλύματα της κροκίνης δεν προκάλεσε σημαντικές αλλαγές στις τιμές του PRI ούτε των λεμφοκυττάρων των λευχαιμικών 
ασθενών, αλλά ούτε και των λεμφοκυττάρων της μάρτυρος. Αντίθετα μετά από την επίδραση της κροκίνης η συχνότητα 
των SCEs παρουσίασε στατιστικά σημαντική μείωση στα λεμφοκύτταρα και των τριών ασθενών, ενώ στα λεμφοκύτταρα 
της μάρτυρος μια μικρή αύξηση. Η δράση αυτή της κροκίνης, τουλάχιστον στις υπό μελέτη συγκεντρώσεις, θα μπορούσε 
να χαρακτηριστεί κυτταροπροστατευτική, αλλά όχι κυτταροστατική, αφού δεν προκάλεσε σημαντικές αλλαγές στο ρυθμό 
πολλαπλασιασμού των κυττάρων αυτών. 
Λέξεις Κλειδιά: Κροκίνη, Χρωματιδιακές ανταλλαγές, Χρόνια λεμφοκυτταρική λευχαιμία.
Κυτταρογενετική συμπεριφορά της κροκίνης σε καλλιεργημένα λεμφοκύτταρα 
ασθενών με λευχαιμία.
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